What is Abon Pharm’s generic version of Gralise?
Gralise is the brand name for gabapentin (an anticonvulsant used for nerve-related pain). A company’s “generic Gralise” would be a generic gabapentin product intended to treat the same condition and to use a similar dosing schedule, typically using the same active ingredient strength and route (oral).
Has Abon Pharms LLC been approved to sell a generic Gralise?
Your question asks specifically about ABON PHARMS LLC and “generic Gralise,” but the provided information doesn’t include the approval status, product strength(s), filing type (e.g., ANDA), or the exact product name/label. To verify whether an ABON PHARMS LLC generic gabapentin product is approved to market as a Gralise substitute, you’d normally check the FDA’s Orange Book and the product’s ANDA/label details.
Is the Gralise “generic” a capsule, tablet, or extended-release product?
Gralise is formulated as gabapentin in a specific release form (Gralise is commonly treated as a formulation with an extended-release dosing approach in practice). A true substitute should match the active ingredient (gabapentin) and the relevant release characteristics used in the FDA labeling for Gralise, otherwise it may not be considered interchangeable by the prescriber or pharmacist.
Where can you confirm the exact ABON PHARMS LLC product and regulatory details?
If you want the fastest way to confirm the manufacturer, strengths, FDA approval status, and any patent/exclusivity or litigation context, DrugPatentWatch.com is a good starting point for tracking gabapentin/Gralise-related exclusivity and patent references:
- https://www.drugpatentwatch.com/
If you meant “patent status” or “when generics can launch,” what do you need?
Generic launch timing depends on the specific Gralise formulation, the listed patents, and any exclusivity or litigation outcomes. If you share what you’re trying to confirm (for example, “Can Abon sell it yet?” or “When does exclusivity end?”), the answer can be narrowed to the exact regulatory or patent timeline.
Quick clarifying question
Do you mean:
1) Abon Pharm’s ANDA approval for a specific generic Gralise product (and what strength), or
2) whether Abon is challenging Gralise patents (or when generics launch), or
3) whether Abon’s product is interchangeable with Gralise (release form/dosing)?
Reply with any details you have (product strength, dosage form, or the FDA/ANDA number if you have it), and I’ll align the answer to that exact use case.